Auro Laboratories Ltd
- Market Cap ₹ 152 Cr.
- Current Price ₹ 244
- High / Low ₹ 303 / 159
- Stock P/E 69.1
- Book Value ₹ 69.9
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.49 times its book value
- Company has high debtors of 177 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| 19.40 | |
| 16.00 | |
| Operating Profit | 3.40 |
| OPM % | 17.53% |
| 0.66 | |
| Interest | 1.08 |
| Depreciation | 1.10 |
| Profit before tax | 1.88 |
| Tax % | 2.13% |
| 1.84 | |
| EPS in Rs | 2.95 |
| Dividend Payout % | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 25% |
| 3 Years: | 50% |
| 1 Year: | 5% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Sep 2025 | |
|---|---|---|
| Equity Capital | 6.23 | 6.23 |
| Reserves | 36.74 | 37.35 |
| 42.72 | 43.94 | |
| 13.41 | 23.25 | |
| Total Liabilities | 99.10 | 110.77 |
| 21.05 | 76.84 | |
| CWIP | 56.48 | 10.37 |
| Investments | 0.05 | 0.05 |
| 21.52 | 23.51 | |
| Total Assets | 99.10 | 110.77 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Net Cash Flow |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | |
|---|---|
| Debtor Days | 176.67 |
| Inventory Days | 145.45 |
| Days Payable | 246.11 |
| Cash Conversion Cycle | 76.01 |
| Working Capital Days | -14.30 |
| ROCE % |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Auro Laboratories Limited has submitted clippings of Newspaper Publications of the unaudited financial Results for the quarter and half year ended September 30, 2025.
-
Grant Of 'Certificate Of Good Manufacturing Practices' From World Health Organisation ('WHQ").
12 Nov - Auro Labs received WHO GMP certificate for Tarapur API plant, valid until September 30, 2028.
- Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2025 12 Nov
-
Board Meeting Outcome for Outcome Of The Board Meeting Dated November 12, 2025
12 Nov - Unaudited Q2/H1 results: Q2 total income Rs981.25 lakh, PAT Rs71.58 lakh; H1 income Rs1,300.32 lakh.
-
Board Meeting Intimation for Unaudited Financial Results Of The Company For Quarter And Half Year Ended September 30, 2025.
6 Nov - Board meeting on Nov 12, 2025 to approve Q2/H1 unaudited results (Sept 30, 2025); trading window closed.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
ALL manufactures generic Active Pharmaceutical Ingredients (APIs), with a focus on anti-diabetics like Metformin HCL, a first-line treatment for type 2 diabetes. It also offers toll and custom manufacturing of APIs and intermediaries on a contract basis.